MetaVia Inc. (MTVA)
NASDAQ: MTVA · Real-Time Price · USD
1.560
+0.040 (2.63%)
At close: Apr 24, 2026, 4:00 PM EDT
1.520
-0.040 (-2.56%)
After-hours: Apr 24, 2026, 7:51 PM EDT
MetaVia Employees
MetaVia had 8 employees as of December 31, 2025. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,621,625
Market Cap
8.06M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 8 | -1 | -11.11% |
| Dec 31, 2024 | 9 | 1 | 12.50% |
| Dec 31, 2023 | 8 | 6 | 300.00% |
| Dec 31, 2022 | 2 | -3 | -60.00% |
| Dec 31, 2021 | 5 | -2 | -28.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 41 |
| Processa Pharmaceuticals | 12 |
| TransCode Therapeutics | 7 |
| Immuron | 7 |
| Enveric Biosciences | 6 |
| Creative Medical Technology Holdings | 4 |
| Acurx Pharmaceuticals | 4 |
| Silo Pharma | 3 |
MTVA News
- 14 days ago - MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity - PRNewsWire
- 4 weeks ago - MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 5 weeks ago - MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control - PRNewsWire
- 6 weeks ago - MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035 - PRNewsWire
- 7 weeks ago - MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum - PRNewsWire
- 2 months ago - MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference - PRNewsWire
- 2 months ago - MetaVia Secures Dozens Of Patents Through 2041 For Obesity Drug - Benzinga
- 2 months ago - MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 - PRNewsWire